Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

19.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.9K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

136
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
136

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of Hyperlipidemia-Related <i>PCSK9</i>, <i>APOE</i>, and <i>LRP8</i> Variants in Restenosis after Stent Implantation in Male Patients: A Case-Control Study.

Molecular syndromology·2026
Same author

Creatinine and hemoglobin/creatinine ratio as predictors of 12-month recurrence after direct visual internal urethrotomy for short-segment (<2 cm) bulbar urethral strictures.

Urologia·2026
Same author

Exercise Stimulates <i>PINK-1, PARKIN, MFN-1</i>, and <i>ATG-3</i> Genes Expression Despite High-fat Diet: Tissue-specific Responses.

In vivo (Athens, Greece)·2026
Same author

Predictors of Pyelonephritis in Patients with Urolithiasis: A Retrospective Case-Control Study.

Surgical infections·2026
Same author

Development of a calibrated logistic regression clinical risk score for predicting postoperative sepsis following retrograde intrarenal surgery.

World journal of urology·2026
Same author

Predictive accuracy of SIRS, MEWS, and NEWS for intensive care unit admission to patients with stone-induced obstructive pyelonephritis: a retrospective cohort study.

Urolithiasis·2026

Related Experiment Video

Updated: Apr 8, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K

Distribution of PD-1.5 Gene Variant (rs2227981): A Possible Approach for Risk Assessment in Bladder Cancer.

Kemal Kayar1, Levent Verim2, Dilara Sonmez3

  • 1Department of Urology, Haydarpaşa Numune Training and Research Hospital, 34668 Istanbul, Turkey.

Archivos Espanoles De Urologia
|April 7, 2026
PubMed
Summary

The PD-1.5 (rs2227981) gene variant may affect bladder cancer risk in Turkish individuals. The TT genotype is linked to higher risk, while the C allele offers protection against bladder cancer.

Keywords:
bladder cancerpolymorphismprogrammed cell death 1 receptorsingle nucleotide polymorphism

More Related Videos

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.7K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K

Related Experiment Videos

Last Updated: Apr 8, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.7K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K

Area of Science:

  • Genetics
  • Oncology
  • Immunology

Background:

  • Immune checkpoint pathways, particularly programmed death-1 (PD-1), are crucial in tumor immune evasion.
  • Genetic variations in PD-1 might influence an individual's susceptibility to cancer.

Purpose of the Study:

  • To investigate the association between the PD-1.5 (rs2227981) polymorphism and the risk of developing bladder cancer (BC).
  • To evaluate the role of this genetic variant in the Turkish population.

Main Methods:

  • The study involved 151 participants: 53 BC patients and 98 healthy controls.
  • Genotyping of the PD-1.5 (C/T) polymorphism was performed using PCR-RFLP.
  • Logistic regression models were used to analyze genotype and allele distributions and calculate odds ratios (ORs) and confidence intervals (CIs).

Main Results:

  • The TT genotype was significantly more frequent in BC patients compared to controls (p=0.023).
  • The C allele was less frequent in patients (p=0.039) and was associated with a reduced risk of BC (OR=0.388, p=0.043).
  • After adjusting for age, sex, and smoking, the C allele remained a protective factor (aOR=0.319, p=0.045).

Conclusions:

  • The PD-1.5 (rs2227981) polymorphism influences bladder cancer susceptibility in the Turkish population.
  • The TT genotype is associated with increased BC risk, whereas the C allele demonstrates a protective effect.
  • PD-1.5 may serve as a genetic marker for BC risk, warranting further investigation in larger cohorts.